RTP Mobile Logo
Hematologic Oncology Update, Issue 4, 2010
Released January 2011

Featuring interviews with Drs Hagop M Kantarjian, Steven M Horwitz, Richard I Fisher and Michele Cavo. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of therapeutic strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES
    • Apply the results of emerging clinical research to effectively integrate novel agents and regimens into the management of myelodysplastic syndromes.
    • Identify early mortality in acute promyelocytic leukemia (APL), and formulate optimal management strategies for APL.
    • Optimize the management of chronic lymphocytic leukemia through the rational integration of prospective Phase III and Phase II data.
    • Outline the classification of T-cell lymphomas, and incorporate recent research results into the management of T-cell lymphoma.
    • Summarize the rational use of proteasome inhibitors and immunomodulatory agents in the management of multiple myeloma.
    • Discuss recently presented Phase III data on induction and maintenance therapy in the management of follicular lymphoma.
    • Counsel appropriately selected patients about the availability of ongoing clinical trials in which they may be eligible to participate.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr KantarjianPaid Research: Bristol-Myers Squibb Company, Genzyme Corporation, Novartis Pharmaceuticals Corporation. Dr HorwitzConsulting Agreements: Allos Therapeutics, Celgene Corporation, Millennium Pharmaceuticals Inc; Paid Research: Allos Therapeutics, Genzyme Corporation. Dr Fisher Consulting Agreements: Millennium Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc. Prof CavoConsulting Fees, Honoraria and Speakers Bureau: Celgene Corporation, Janssen-Cilag EMEA, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation.

    EDITOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium Pharmaceuticals Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2011
    Expiration date: January 2012

Acknowledge and close

Hematologic Oncology Update, Issue 4, 2010
Released January 2011

Featuring interviews with Drs Hagop M Kantarjian, Steven M Horwitz, Richard I Fisher and Michele Cavo. (Text and Audio Content)